Zinc oxide nanoparticles modulate the gene expression of ZnT1 and ZIP8 to manipulate zinc homeostasis and stress-induced cytotoxicity in human neuroblastoma SH-SY5Y cells.

Zinc ions (Zn2+) are important messenger molecules involved in various physiological functions. To maintain the homeostasis of cytosolic Zn2+ concentration ([Zn2+]c), Zrt/Irt-related proteins (ZIPs) and Zn2+ transporters (ZnTs) are the two families of proteins responsible for decreasing and increasing the [Zn2+]c, respectively, by fluxing Zn2+ across the membranes of the cell and intracellular compartments in opposite directions. Most studies focus on the cytotoxicity incurred by a high concentration of [Zn2+]c and less investigate the [Zn2+]c at physiological levels. Zinc oxide-nanoparticle (ZnO-NP) is blood brain barrier-permeable and elevates the [Zn2+]c to different levels according to the concentrations of ZnO-NP applied. In this study, we mildly elevated the [Zn2+]c by ZnO-NP at concentrations below 1 μg/ml, which had little cytotoxicity, in cultured human neuroblastoma SH-SY5Y cells and characterized the importance of Zn2+ transporters in 6-hydroxy dopamine (6-OHDA)-induced cell death. The results show that ZnO-NP at low concentrations elevated the [Zn2+]c transiently in 6 hr, then declined gradually to a basal level in 24 hr. Knocking down the expression levels of ZnT1 (located mostly at the plasma membrane) and ZIP8 (present in endosomes and lysosomes) increased and decreased the ZnO-NP-induced elevation of [Zn2+]c, respectively. ZnO-NP treatment reduced the basal levels of reactive oxygen species and Bax/Bcl-2 mRNA ratios; in addition, ZnO-NP decreased the 6-OHDA-induced ROS production, p53 expression, and cell death. These results show that ZnO-NP-induced mild elevation in [Zn2+]c activates beneficial effects in reducing the 6-OHDA-induced cytotoxic effects. Therefore, brain-delivery of ZnO-NP can be regarded as a potential therapy for neurodegenerative diseases.

Introduction

Zinc ion (Zn2+) is essential for all living organisms and is the second most abundant transition element in human. It is a cofactor in many proteins regulating their catalytic activities and structure. In addition, recent emerging evidence has shown that Zn2+ is a messenger in regulation of many cellular activities such as cell cycle, cell proliferation, differentiation and death via different signaling pathways [1, 2]. Cytosolic Zn2+ concentration ([Zn2+]c) changes during cell cycle, differentiation and cell death [3]. During cell proliferation, the tyrosine phosphatases are suppressed by a small elevation of [Zn2+]c to activate ERK pathway [4]. A number of transcription factors, such as p53, contain Zn2+ binding motifs affecting cell cycle and survival [5].

The paradoxical, but vital, roles of Zn2+ in nervous system have gained recognition recently [6, 7]. Zn2+ is essential for neurogenesis, neuronal differentiation and synaptic transmission. The inhibition of synaptic Zn2+ signaling in hippocampus and amygdala by Zn2+ chelators affects cognition [8]. Zn2+ deficiency reduces neurogenesis and associates with neuronal dysfunction. A correlation between Zn2+ deficiency and depression has been demonstrated in both clinical studies and animal models [9, 10]. In contrast, high Zn2+ levels block mitochondrial function and induce apoptosis in the development of pathophysiology of CNS disorders including epilepsy, schizophrenia and Alzheimer's Disease [11]. At cellular level, high dose of Zn2+ is neurotoxic causing cell death [12-14] and Zn2+ deficiency causes caspase-dependent apoptosis in human neuronal precursor cells [15, 16]. Zn2+ supplementation significantly reduces spinal cord ischemia-reperfusion injury in rats [17]. However, dietary Zn2+ supplementation has restrictions and limitations in crossing brain-blood barrier (BBB), which has limited permeability for Zn2+, especially when the desired final Zn2+ level is higher than physiological levels [18]. Thus, controlled and targeted delivery of Zn2+ is highly desirable.

Nanoparticles (NP) technologies have been used for the targeted delivery of chemicals [19]. In nervous system, polylactide-co-glycolide or BBB ligand specific-modified polylactide polymers are used to carry Zn2+ across BBB [18, 19]. However, the rate is slow, the cellular or brain entrance are evidenced after several days [19]. We have previously demonstrated the entrance of zinc oxide-NP (ZnO-NP) into brain via olfactory bulb in rat and elevates the [Zn2+]c in cultured cells [20]. Therefore, ZnO-NP has the potential to be a potent means for Zn2+ delivery to regulate [Zn2+]c homeostasis in the central nervous system.

The cellular uptake of ZnO-NP into intracellular compartments is via endocytosis followed by dissolution that occurs in acidic compartments to convert ZnO-NP to Zn2+ [20]. Two classes of proteins are implicated in Zn2+ transport for [Zn2+]c homeostasis: solute-linked carrier 30 (SLC30, Zn transporter (ZnT)) and SLC39 (Zrt/Irt-realted proteins (ZIP)) decrease and increase the [Zn2+]c, respectively, by fluxing Zn2+ across the membranes of cell and intracellular organelles in opposite directions. The ZIP proteins then transport the accumulated Zn2+ in these acidic compartments to the cytosol and ZnT proteins work corporately to flux Zn2+ out of the cytosol. Therefore, ZnO-NP may be different from direct Zn2+ application in regulating expression levels of Zn2+ transporters to control Zn2+ homeostasis.

ZnO-NP at high dosage causes apoptosis in lung [21] and neural stem cells [13] and interferes with the ion channel activities in primary cultured rat hippocampal neurons [22]. However, toxicity is not seen under exposure to ZnO-NP at low doses, such as 6 ppm (70 μM) [13], or 10 μM [20]. The importance of Zn2+ to normal functioning of the central nervous system is increasingly appreciated [9, 15]. In this report, we mildly elevated the [Zn2+]c in human neuroblastoma cells, SH-SY5Y, by ZnO-NP at concentrations below 1 μg/ml. ZnO-NP treatment greatly enhanced the expression level of ZnT1 and less affected the expression of ZIP8. ZnO-NP treatment decreased the basal level of reactive oxygen species (ROS) and the expression ratio of Bax/Bcl-2. In addition, ZnO-NP treatment recued the cell death caused by the 6-hydroxy dopamine (6-OHDA). Therefore, BBB-permeable ZnO-NP provides a therapeutic strategy to treat neurodegeneration disorders by fin-tuning the [Zn2+]c.

Materials and methods

Chemicals

ZnO-NPs were purchased from Sigma-Aldrich Co. (St. Louis, MO, USA). Their preparation protocols were described in our previous work [21]. The size range of ZnO-NP in solution was from 20 to 80 nm with an average of 45 nm. SH-SY5Y neuroblastoma cells were purchased from the American Type Culture Centre CRL2266 (Manassas, VA, USA). FluoZin-3-AM, Lipofectamine 2000®, reverse transcriptase III and TRIzol® reagent were purchased from Invitrogen Co. (Carlsbad, CA, USA). RNase-free DNAse I and RNeasy purification columns were purchased from Qiagen Inc. (Valencia, CA, USA). Random hexamer primers were obtained from Fermentas Inc. (Burlington, Canada). iQ SYBR Green Supermix was obtained from Bio-Rad Inc. (Hercules, CA, USA). Other chemicals were obtained from Merck KGaA (Darmstadt, Germany) otherwise indicated.

Cell culture

Human neuroblastoma SH-SY5Y cells were cultured in minimal essential medium (Gibico 41500–034) supplemented with F12 nutrient mixture (Gibico 21700–075) and 10% fetal bovine serum. The cells were kept in a humidified 5%-CO2 incubator at 37 ºC [20].

[Zn2+]c Measurements

Suspended cells were incubated in a Loading buffer (in mM, NaCl 150, glucose 5, Hepes 10, MgCl2 1, KCl 5, CaCl2 2.2, pH7.3) containing 10 μM of FluoZin-3-AM at 37°C for 30 minutes. After washing out the FluoZin-3-AM by centrifugation and resuspending the cell in Loading buffer, the changes in the fluorescence intensity were recorded as described before [20].

RT-PCR assay

RNA extraction and reverse transcription were performed following the protocols suggested by the manufactures. The primers for the polymerase chain reactions (PCR, Q-Amp™ 2x HotStart PCR Master Mix) were listed in S1 Table in S1 File. The products were separated by electrophoresis on 2% agarose gels, stained with ethidium bromide, and photographed with ultraviolet trans-illumination. For quantitative PCR (qPCR), the kit used was IQ2 Fast qPCR System and the instrument was from Illumina Inc. (Eco™ Real-time PCR system) [23].

ROS measurements

To quantify the production of ROS, we loaded the cells with 2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA, Molecular Probes®) and incubated at 37ଌ, 5% CO2 for 30 minutes. After replacing the medium, 6-OHDA or H2O2 were added. The fluorescence intensities were measured by a microplate reader (Glomax-multidetection system, Promega, USA) with excitation at 485 nm and emission at 500–560 nm.

ZIP and ZnT shRNA knockdown

Plasmids expressing short hairpin RNAs (shRNA) against ZIP8 and ZnT1 were purchased from National RNAi Core Facility, Academia Sinica, Taiwan, and the target sequences of these shRNAs (4 for ZIP and 5 for ZnT) were listed in S2 Table in S1 File. Lipofectamine 2000® was used to transfect these plasmids into SH-SY5Y cells [24]. An apoplasmid was used as negative control.

MTT assay

The MTT assay, an index of cell viability and cell growth, is based on the ability of viable cells to reduce MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) [25]. All samples were assayed in triplicate from 5 batches of cells. The total time of ZnO-NP treatment was 24 hr and 6-OHDA was added at 18th hr. To enhance cell death caused by 6-OHDA, cells were incubated in a medium containing 0.5% of serum. For cells after shRNA transfection, the serum was 5% during all experiments.

Statistical analysis

Statistical analysis was performed using one-way analysis of variance and significant differences were assessed by Student's t test. A p value less than 0.05 was regarded as statistically significant.

Results

ZnO-NP elevates [Zn2+]c in cultured SH-SY5Y cells

To examine ZnO-NP at low doses can elevate [Zn2+]c in cultured human neuroblastoma SH-SY5Y cells, we loaded the cells with FluoZin3, a Zn2+-sensitive dye, and monitored the changes in fluorescence intensities (Fig 1). The addition of ZnO-NP (0.081 and 0.814 μg/ml, n = 3 each) increased the fluorescence intensity gradually during the 200-s recording period in a concentration-dependent manner. For 25-hr long-term treatment, the fluorescence intensities measured reached a maximum in 6 hr when treated with different concentrations of ZnO-NP (0.081, 0.814, and 8.14 μg/ml, n = 3 each and statistical symbols were shown in S1 Fig in S1 File). These results reveal that ZnO-NP apparently elevates the [Zn2+]c transiently in a concentration- and time-dependent mode even at low concentrations.

Fig 1

ZnO-NP exposure induces a transient elevation of [Zn2+]c in SH-SY5Y cells.

We loaded the cells with FluoZin-3 and monitored the changes of the fluorescence intensities from a group of suspended cells stimulated with different concentrations of ZnO-NPs. A. The short-term [Zn2+]c responses. ZnO-NP (0, 0.081, and 0.814 μg/ml) were added at the beginning of the recording and the fluorescence intensities were normalized to the value at the time zero (F/F0). B. Normalized [Zn2+]c elevation after long-term exposure of ZnO-NP. The fluorescence intensities from ZnO-NP-treated suspension cells were normalized to the control group without ZnO-NP treatment (Normalized [Zn2+]c) at different time after ZnO-NP exposure. Data presented were Mean ± SEM from 3 batches of cells; *, **, and *** indicates the Student’s t-test p value < 0.05, 0.01, and 0.001, respectively.

ZnT1 and ZIP8 regulate the ZnO-NP-induced [Zn2+] responses in SH-SY5Y cells

ZIPs and ZnTs play important roles in maintaining the [Zn2+]c homeostasis. We first characterized the expression levels of ZnT and ZIP isoforms in cultured SH-SY5Y cells by RT-PCR and the results showed significant expressions of ZnT, ZnT, ZnT, ZnT, ZnT, ZnT, ZnT and ZnT (S2A Fig in S1 File) and ZIP, ZIP, ZIP, ZIP, ZIP, ZIP, ZIP, ZIP, ZIP, ZIP and ZIP (S2B Fig in S1 File). ZnT1 is the main transporter at the plasma membrane to efflux Zn2+ out of cells and lowers the [Zn2+]c [26]; ZIP8 presents in the synaptic vesicles and lysosomes to transport Zn2+ from intracellular compartments to the cytosol [27, 28]. Since endocytosis is the main route for ZnO-NP entrance into the cell and dissolution into Zn2+ occurs in an acidic compartment [20], we focused on characterizing the involvement of ZnT1 and ZIP8 in modulating the ZnO-NP-induced [Zn2+]c response in SH-SY5Y cells (Fig 2). We adopted qPCR to investigate the mRNA levels of ZnT and ZIP in SH-SY5Y cells after the addition of ZnO-NP of different concentrations (Fig 2A & 2B, n = 3 for each concentration). The average results show that a low-dose of ZnO-NP (0.081 μg/ml) elevated the expression levels of ZnT and ZIP transiently in 6 hr (p < 0.05) and then declined to a basal level after 24 hrs. High doses of ZnO-NP (0.814 and 8.14 μg/ ml) treatment maintained the expression of ZnT at a level 4~8 fold higher than the control group (p < 0.05) during the 24-hour exposure period. ZnO-NP at 0.814 μg/ml elevated and maintained the expression of ZIP at a level 2–3 fold higher than the control group (p < 0.05), however, at 8.14 μg/ml, ZnO-NP had little effect on the expression of ZIP. These results reveal that ZnO-NP exposure differentially enhances the expression of ZnT and ZIP.

Fig 2

Knockdown the expressions of specific Zn2+ transporters interfere [Zn2+]c responses in SH-SY5Y cells.

A. and B. The expression levels of ZnT1 and ZIP8, respectively. Cells were treated with different concentrations of ZnO-NP for 0, 6 and 24 hr and the mRNA levels of ZnT and ZIP were analyzed by RT-PCR. The expression levels were normalized to that of β-actin. C. and D. Expression knockdown of ZnT1 and ZIP8, respectively. Specific shRNAs against ZnT (H1-5) and ZIP (H6-9) were delivered into the cells for 1 day and the protein levels were examined by Western blot (upper panel). The intensities of each protein bands were normalized to that of β-actin (lower panel). E. [Zn2+]c responses in transfected cells. Cells were transfected with H5 and H9 shRNAs for 1 day and then loaded with FluoZin3. The changes in the fluorescence intensities (ΔF/F0) induced by ZnO-NP (0.814 μg/ml) were calculated. Data presented were Mean ± S.E.M from 3 bathes of cells. *, **, ***: p < 0.05, 0.01, and 0.001, respectively (Student’s t-test) when compared to the control group.

To verify the contributions of these transporters in regulating the [Zn2+]c responses induced by ZnO-NP, we delivered specific shRNAs into the cells to reduce the translation of ZnT and ZIP (Fig 2C & 2D, respectively) (The original images of the Western blot were shown in S3 Fig in S1 File). The results of the Western blots revealed that most of these shRNAs decreased the protein levels of ZnT (H1-5) and ZIP (H6-9); among them, H5 and H9 were the most effective shRNAs in reducing the protein levels of ZnT1, by 88%, and ZIP, by 70%, respectively. Treating transfected SH-SY5Y cells with ZnO-NP (0.814 μg/ml, Fig 2E, n = 3), the averaged changes in [Zn2+]c, comparing to the control group, was about 4-fold higher in cells expressing H5 (p < 0.001) and mostly abolished in cells expressing H9 (p < 0.001). It is likely that cells change the expression levels of these transporters to regulate the [Zn2+]c in response to different stimulations.

ZnO-NP at a low dose increases the Bax/Bcl-2 expression level

To characterize the toxicity of ZnO-NP on SH-SY5Y cells, we treated the cells with different concentrations of ZnO-NP for 24 hr and monitored the viability by MTT assay (Fig 3A). The results show that ZnO-NP exposure reduced the viability in a dose dependent manner with an EC50 of 6.8 ± 0.2 μg/ml (n = 15). Under 2 μg/ml, ZnO-NP had little effect on cell viability. We then examined the expression levels of Bax and Bcl-2 by qPCR in SH-SY5Y cells treated with ZnO-NP at 0.081 and 0.814 μg/ml for 24 hr (Fig 3B). The amounts of the PCR products expressed from Bax and Bcl-2 decreased and increased, respectively, as the concentrations of ZnO-NP increased (the original images of the agarose gel analysis of the PCR products were shown in the S4 Fig in S1 File). After normalization, the Bax/Bcl-2 expression ratio were significantly decreased to 0.69 ± 0.12 (p < 0.01) and 0.34 ± 0.08 (p < 0.001), respectively. In contrast, ZnO-NP at 8.14 μg/ml significantly increased the ratio to 1.49 ± 0.2 (n = 3, p < 0.01, not shown). Therefore, that ZnO-NP at low non-lethal doses decreases the Bax/Bcl-2 ratio indicating the blockage of apoptosis pathway.

Fig 3

Low-dose ZnO-NP exposure reduces basal apoptosis signal in SH-SY5Y cells.

A. Dose-dependent cell viability. After a 24-hr ZnO-NP exposure at different concentrations, the cell viability was analyzed by an MTT assay. The dose-dependence were fitted by a Boltzmann equation with an EC50 of 6.8 ± 0.2 μg/ml. Data presented were Mean ± SEM from 5 batches of cells. B. The Bax/Bcl-2 ratio. Cells were treated with ZnO-NP for 24 hr and then the mRNA were collected for RT-PCR to analyze the expression levels (upper panel) of Bax and Bcl-2. The intensities of the PCR products were normalized to the level of β-actin and then used to calculate the Bax/Bcl-2 ratio (Lower panel). Data presented were Mean ± S.E.M (n = 3). ** and ***: p < 0.01 and 0.001, respectively, by Student’s t-test when compared to the control group.

ROS accumulation can trigger the expression of apoptosis-related genes. We then examined the intracellular ROS levels by loading the cells with H2DCFDA and monitored the changes in the fluorescence intensities in 2 hr (S5 Fig in S1 File). For control cells without ZnO-NP treatment, the ROS level increased over the recording period; in the presence of ZnO-NP (0.081 and 0.814 μg/ml), the ROS levels at the same duration were lower than that of the control group. These findings suggest that a low-dose exposure of ZnO-NP elicits beneficial effects in cells to reduce the oxidation stress and protect cells from death.

ZnO-NP counteracts stress-induced ROS generation and cell death in SH-SY5Y cells

The uptake of 6-OHDA, an analog of dopamine, into cells through dopamine transporters triggers the production of ROS and causes cell death. To verify ZnO-NP has a protective effect on the 6-OHDA-induced cell death, we pretreated the SH-SY5Y cells with a low dose of ZnO-NP (0.081 and 0.814 μg/ml) for 18 hr then 6-OHDA of different concentrations were added for another 6 hr (Fig 4A, n = 5). The results show that 6-OHDA at 50 and 100 μM significantly decreased the cell viability from 99.9 ± 7.0% of control group to 67.3 ± 10.3 (p < 0.01) and 42.1 ± 4.3 (p < 0.01), respectively. ZnO-NP pretreatment counteracted the 6-OHDA-induced cell death but not significant when 6-OHDA applied was 50 μM; in contrast, for 6-OHDA at 100 μM, the viabilities were significantly enhanced to 64.2 ± 12.9 (p < 0.01) and 53.4 ± 12. 7% (p < 0.05) by ZnO-NP at 0.081 and 0.814 μg/ml, respectively. In addition, ZnO-NP (0.081 μg/ml) pretreatment significantly reduced the ROS level to 80 ± 6% of the Control group (n = 15, p < 0.05) and 6-OHDA treatment greatly elevated the ROS level to 135 ± 10% (n = 15, p < 0.05) (Fig 4B). ZnO-NP pretreatment could significantly reduce this increment to 98 ± 11% (n = 15, p < 0.05) (Fig 4B). Furthermore, ZnO-NP pretreatment reversed the effects of H2O2 in cell survival and ROS production (S6 Fig in S1 File). We then used RT-PCR to examine the expression level of p53, a transcription factor involved in the ROS-activated apoptosis pathway [29], in SH-SY5Y cells (Fig 4C and the original images were shown in S7 Fig in S1 File). After normalization to that of the control group, 6-OHDA treatment significantly increased the expression level of p53 to 1.5 ± 0.3 (n = 3, p < 0.01) and this increment could be reduced by the pretreatment of ZnO-NP (0.081 μg/ml) to 0.9 ± 0.0 (n = 3, p < 0.05). These results suggest that ZnO-NP at a concentration below 1 μg/ml suppresses the production of ROS and reduced the expression of p53 to facilitate cell survival.

Fig 4

ZnO-NP suppresses 6-OHDA-induced cytotoxicity in SH-SY5Y cells.

Cells were incubated in a medium containing ZnO-NP (0, 0.081, 0.814 μg/ml) for 24 hr and 6-OHDA (50 or 100 μM) was added at 18th hr. A. Cell viability. The viability was measured by an MTT assay from 5 batches of cells. B. Normalized ROS production. Data presented were Mean ± SEM (n = 15). C. p53 mRNA levels. The ZnO-NP used was 0.081 μg/ml and cells were harvested for RT-PCR. The density of p53 products were normalized to that of β-actin and Control group (n = 3). The significance was analyzed by Student’s t-test; *, **: p < 0.05 and 0.01, respectively, when compared to the control group without 6-OHDA treatment or as indicated.

ZnT1 and ZIP8 knockdown affected 6-OHDA-induced cytotoxicity

To verify the importance of ZnO-NP-induced elevation of [Zn2+]c in protecting cells from death, we transfected the SH-SY5Y with shRNAs against ZnT and ZIP, then examined the cell viability under 6-OHDA treatment with MTT assay (Fig 5, n = 15). Because of the damages caused by the transfection reagents, the culture medium contained 5% of serum during the experiment. The results show that 6-OHDA (50 μM) treatment decreased the viability from 100.8 ± 4.7 to 87.6 ± 5.1% (p < 0.01). Knockdown the expression of ZnT1 recused the cell death caused by 6-OHDA to a level similar to that of the control group and the addition of ZnO-NP did not enhance the viability. In contrast, ZIP knockdown did not have such a protective effect in 6-OHDA-induced cell death (100.0 ± 1.9 vs. 94.1± 3.0%) and the addition of ZnO-NP did not reverse the toxic effect of 6-OHDA. As shown in Fig 2E, knockdown the expression of ZnT and ZIP enhanced and suppressed the ZnO-NP-induced elevations of [Zn2+]c, respectively. Therefore, the release of Zn2+ from the acidic compartments by ZIP8 and the elevation of [Zn2+]c facilitated by ZnT1 are important in enhancing the viability of cells under different challenges.

Fig 5

ZnO-NP altered 6-OHDA-induced cytotoxicity in cells with transporter knockdown.

H5 and H9 shRNAs were transfected into SH-SY5Y cells for 24 hr to knock down the expression of ZnT and ZIP, respectively. Cells were then treated with ZnO-NP of different concentrations for 18 hr and then 6-OHDA (50 μM) was added for another 6 hr. The cell viability was determined by MTT assay. Data presented were Mean ± SEM (n = 5 batches) and the significance were analyzed by Student’s t-test; * and **: p < 0.05 and 0.01, respectively, when compared to the group without 6-OHDA treatment.

Discussion

This study finds that ZnO-NP potently induced the expressions of ZnT and ZIP to modulate [Zn2+]c, a crucial parameter for cytoviability in human neuroblastoma SH-SY5Y cells. Below lethal dosage under 1 μg/ml, ZnO-NP transiently elevated the [Zn2+]c and decreased the Bax/Bcl-2 expression ratio. In addition, ZnO-NP suppressed the cytotoxicity, ROS production and p53 gene expression induced by 6-OHDA or H2O2. These results suggest the cell-protective function of ZnO-NP at low dosages against oxidative stresses and support a therapeutic strategy by delivering ZnO-NP into the CNS to suppress the development of neuropathological disorders.

Zn2+ trafficking was investigated in these experiments. ZnO-NP-induced changes of [Zn2+]c were studied in cells transfected with shRNA against ZnT to illustrate the role of ZnT1 for the efflux of Zn2+. [Zn2+]c and the expression of ZnT were coupled; both showed increases under exposure to low doses of ZnO-NP and returned to the basal levels after 24 hr. At high dosage (8.14 μg/ml), ZnO-NP induced a large increase in [Zn2+]c, coupled with an 8-fold increase in ZnT mRNA (at 6 hr). In this case, both the expression level of ZnT and [Zn2+]c remained high throughout the observation period. Moreover, neurotoxicity induced by 6-OHDA was suppressed in the ZnT1-kockdowned cells. Our data show that [Zn2+]c changes are coupled with the ZnT expression levels which are closely related to the neuron-protection activity of Zn2+. ZnT1 is known to be a plasma membrane protein that is enriched in postsynaptic dendritic spines and plays a role in Zn2+ homeostasis in synaptic neuron functions and diseases [30]. Su et al. reported a positive correlation between ZnT1 and Zn2+ content in the spinal cord [31], and ZnT1 is shown to increase significantly with progression of Alzheimer’s disease [32].

Our data suggest that changes in ZnT expression can become a marker for [Zn2+]c disturbance associated with neuroviability. Other ZnTs such as ZnT10, at Golgi, is down-regulated by an elevation of extracellular Zn2+ in SH-SY5Y cells [33]. IL-6 induces a down-regulation of ZnT and enhances the accumulation of Mn2+ that might be correlated with Parkinson’s disease [34]. Further studies on ZnTs, ZIPs, and metallothioneins (MTs), are required to understand their roles in modulating the Zn2+ homeostasis.

We have previously demonstrated the internalization of ZnO-NP by PC12 cells upon exposure to the ZnO-NPs for 10 min. Furthermore, after nasal exposure to airborne ZnO-NP, the NPs are found in rat brain under a transmission electron microscope [20]. We also verify that ZnO-NP elevates [Zn2+]c in both cultured cells and rat white blood cells through endocytosis and subsequent dissolution in acidic compartments such as endosomes [21]. Conversion of ZnO to ions following entrance into lysosomes has also been shown in the studies of Xia et al. in which the labeled ZnO is traced in BEAS-2B cells [35]. Muller et al. also have demonstrated that ZnO dissolves rapidly in a lysosomal fluid at a pH of 5.2 [36].

ZIP8 has been shown to be localized in the lysosomal membrane and synaptosomes [27, 28]. Our data show that ZnO-NP-induced [Zn2+]c changes are greatly suppressed in ZIP-knockdowned cells, illustrating that ZIP is required for intracellular Zn2+ release from those organelles after ZnO-NP was engulfed, which may be the main route for ZnO in elevating [Zn2+]c. The mRNA levels of ZIP and ZnT were positively correlated with the changes in [Zn2+]c under exposure to ZnO-NP below 1 μg/ml. At a high dose of ZnO-NP (8.14 μg/ml), the expression of ZIP was small in contrast to [Zn2+]c response and ZnT expression. The low level of ZIP8 prevent additional Zn2+ fluxing to the cytosol and further cellular damage. These results suggest that there is a negative feedback between elevation of [Zn2+]c and the expression of ZIP.

ROS is known to cause DNA damage that activates the p53-linked apoptosis pathway through phosphorylation by ATM. Bcl-2 has been shown to be coupled with the pro-survival pathway to counteract the effects of mitochondrial damages induced by Bax. In addition, silencing the expression of ZnT, but not ZIP, can not only enhance the ZnO-NP-induced [Zn2+]c elevation but rescue the 6-OHDA-induced cell death. It is likely that [Zn2+]c response is a perquisite for ZnO-NP to reduce stress-induced cytotoxicity by suppressing ROS generation and augmenting expression of bcl-2.

Zn2+ has been widely shown as a potential antioxidant for suppression of apoptosis [37-44]. In animal brain studies, Zn2+ treatment decreases the Bax/Bcl-2 protein ratio [44]; treating SH-SY5Y cells with a low dose of Zn2+ can reverse a stress-induced increment of DNA fragmentation [12]. Zn2+ supplementation can reduce the levels of ROS to prevent cardiomyocyte apoptosis and congenital heart defects [40]; it also promotes the recovery of spinal cord function [17, 45]. Zn2+ has a protective effect on renal ischemia-reperfusion injury by augmenting superoxide dismutase activity and lowering the Bax/Bcl-2 expression ratio to reduce apoptosis [37]. Therefore, our results support that ZnO-NP, at sub-lethal dosage, causes a mild elevation of [Zn2+]i which has been shown to enhance the expression of metallothioneins [46] and the activity of Zn2+-related superoxide dismutase [47]. Both metallothioneins and dismutase can lower the ROS level leading to the down-regulation of the expression of p53 and Bax/Bcl-2 ratio [47, 48]. In the future, we will further characterize how [Zn2+]i, when elevated to different levels, regulates the ROS production.

In this and previous studies, we show that ZnO-NP dose-dependently exert paradoxical protective and cytotoxic functions through their ability to alter [Zn2+]c and modulate the expression of ZnT and ZIP. Delivering ZnO-NP at a low dose into the central nervous system may provide a practical strategy to elevate the [Zn2+]c for potent neuroprotection. Further studies, both in vivo and in vitro, will be required using more sensitive and selective techniques to measure the homeostasis of [Zn2+]c and to assess the feasibility of using ZnO-NP for clinical application.

(DOCX)

Click here for additional data file.

11 Jun 2020

PONE-D-20-11050

Zinc oxide nanoparticles modulate the gene expression of ZnT1 and ZIP8 to manipulate zinc homeostasis and stress-induced cytotoxicity in human neuroblastoma SH-SY5Y cells

PLOS ONE

Dear Dr. Liu,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

ACADEMIC EDITOR:

The manuscript #PONE-D-20-11050 entitled "Zinc oxide nanoparticles modulate the gene expression of ZnT1 and ZIP8 to manipulate zinc homeostasis and stress-induced cytotoxicity in human neuroblastoma SH-SY5Y cells" has been reviewed for publication in PLoS ONE. The reviewers’ and additional editor comments are copied below.

Please submit your revised manuscript by Jul 26 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

3. Please provide additional information about each of the cell lines used in this work, including source, history and any quality control testing procedures (authentication, characterisation, and mycoplasma testing). For more information, please see http://journals.plos.org/plosone/s/submission-guidelines#loc-cell-lines.

4. To comply with PLOS ONE submission guidelines, in your Methods section, please provide additional information regarding your statistical analyses. For more information on PLOS ONE's expectations for statistical reporting, please see https://journals.plos.org/plosone/s/submission-guidelines.#loc-statistical-reporting.

5. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

Additional Editor Comments (if provided):

1. Please add the number of experiments for each statistical result.

2. In Fig. 4A, the inhibitory effect of ZnO-NP in 6-OHDA-induced cell death does not appear to be in a dose-dependent manner. Please check this.

3. In Fig. 2S, why does the ROS of the control group increase with time? Does the author do any stimulation to this group? Please explain it.

4. In Fig. 4B, I think that ZnO-NP seems to only inhibit basal ROS, but does not affect the 6-OHDA-stimulated ROS production. Please check and explain it.

In addition, please mark the unit of ROS production in the figure.

5. In Fig. 5, 6-OHDA (50 �M) reduced cell viability (~15%), which is inconsistent with the data of Fig. 4A (~40%). This may cause the results of Fig. 5 to be misjudged. Please check and redo it.

6. Please add the statistical symbol in the figures and clearly explain in the legends, including in Fig. 1, 2A, 2B, and 3A. This will increase their credibility.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Generally speaking, this paper is clear and concise. The maintext is perfect and well

written. However, there are several points that should be carefully revised.

1. In figure 4, 5, S2 and S3, the incubation times of ZnO-NP treated cells were difference. The authors should explain why the difference.

2. The authors need to discuss the possible reason or mechanism for explaining why ZnO-NP decreased ROS production and p53 expression.

3. Please indicate the molecular size of ZnT1 and ZIP8 in figure 2. The exact migration position of at least one independent molecular weight marker protein should be indicated with each gel or blot. Each blot panel should retain space above and below the band of interest from the original image.

4. Some spelling errors should be avoided. Such as, in discussion 9th line, “ snRNA” change “shRNA”.

Reviewer #2: Authors investigated the effects of Zinc oxide nanoparticles, which had little cytotoxicity, in cultured human neuroblastoma SH-SY5Y cells and characterized the importance of Zn2+ transporters in 6-hydroxy dopamine (6-OHDA)-induced cell death. The manuscript is well-written, with a significant summary and discussion.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

13 Aug 2020

Questions from academic editor:

Q1. Please add the number of experiments for each statistical result.

Response: Thanks for the suggestion. We have included the number of experiments and statistical results in the main text and figure legends.

Q2. In Fig. 4A, the inhibitory effect of ZnO-NP in 6-OHDA-induced cell death does not appear to be in a dose-dependent manner. Please check this.

Response: The large variations of the results shown in Fig. 4A make it was difficult to evaluate that ZnO-NP suppressed the cell death in a dose-dependent manner. However, Fig. 5 and Fig. S5 show that ZnO-NP at these concentrations had a similar effect in suppressing the cell death and reducing the production of ROS, respectively. Henceforth, it is likely that the protecting effects of ZnO-NP at these concentrations are at the plateau phase against the 6-OHDA-evoked oxidative stresses.

Q3. In Fig. 2S, why does the ROS of the control group increase with time? Does the author do any stimulation to this group? Please explain it.

Response: Fig S2 is now Fig S5. There is no treatment other than the ZnO-NP application in this experiment. The increase may come from the cellular normal metabolism which produces ROS continuously as suggested by the manufacture. Some reports consider this increment as the background and subtract them from the results.

Q4. In Fig. 4B, I think that ZnO-NP seems to only inhibit basal ROS, but does not affect the 6-OHDA-stimulated ROS production. Please check and explain it. In addition, please mark the unit of ROS production in the figure.

Response: Thanks for the suggestion. We reorganized the results by normalizing the responses to that of the control group in each independent batch of cells. The average results showed that ZnO-NP treatment reduced the ROS level to 80 +/- 6% (p < 0.05) and 6-OHDA treatment significantly elevated the ROS level to 135 +/- 10% (p < 0.05). This increment in ROS production was significantly reduced to 98 +/- 11% by ZnO-NP pretreatment (p < 0.05) (n = 15 for each group). Therefore, these results support that a low dose of ZnO-NP enhances the cell survival by reducing the generation of ROS. (Page 10, Lines 216-219)

Q5. In Fig. 5, 6-OHDA (50 uM) reduced cell viability (~15%), which is inconsistent with the data of Fig. 4A (~40%). This may cause the results of Fig. 5 to be misjudged. Please check and redo it.

Response: Sorry for the confusion. The cell survival experiment of Fig. 4A was performed in a medium containing 0.5% of serum in order to reveal the toxicity of 6-OHDA. However, SH-SY5Y cells became fragile after transfection (Fig. 5) and could not survive well in a medium containing 0.5% of serum for 6-OHDA treatment. Thus the experiment shown in Fig. 5 was performed in a medium containing 5% of serum during 6-OHDA treatment. We have modified the manuscript to reveal the difference. (Page 6 Line 130-134; Page 10 Lines 232-234)

Q6. Please add the statistical symbol in the figures and clearly explain in the legends, including in Fig. 1, 2A, 2B, and 3A. This will increase their credibility.

Response: Thanks for the suggestion. Fig. 1B is a line graph shows the changes in the [Zn2+]c during the incubation of ZnO-NP at different concentrations, it was difficult to put statistical symbols besides each data point. Therefore, we plotted the data in a bar graph as shown in the Supplementary Figure S1 to accommodate all of the statistical symbols at each data points. We have added statistical symbols to Fig. 2 A & B. However, as Fig. 3A is the dose response curve, we focused on the curve fitting and the statistical symbol was not included.

Reviewer #1:

1. In figure 4, 5, S2 and S3, the incubation times of ZnO-NP treated cells were difference. The authors should explain why the difference.

Response: We are sorry for the confusion caused by the typos. The total time for ZnO-NP treatment in these experiments was 24 hr and stimulants were added at different time. For 6-OHDA treatment (Fig. 4 and 5), 6-OHDA was added at the 18th hr and the cells was used for MTT and ROS assays at 24th hr (Fig. 4B). For H2O2 treatment, H2O2 was added at the 20th hr for the viability assay (Fig. S4A) and 23rd hr for the ROS production assay (Fig. S4B). We have modified the manuscript to clarify the experiment (Page 6, Lines 129-131; Page 17, Lines 354-357; Legends of Figures S3 & S4).

2. The authors need to discuss the possible reason or mechanism for explaining why ZnO-NP decreased ROS production and p53 expression.

Response: Our results here suggest that a weak-to-mild elevation of [Zn2+]i decreases the generation of ROS and protecting cells from 6-OHDA-induced death. It has been suggested that the elevation of [Zn2+]i can enhance the expression of metallothioneins and the activities of Zn2+-containing superoxide dismutases. Metallothioneins can work as antioxidants and dismutase can reduce the ROS level resulting in the downregulation of apoptosis pathway as indicated by the expression of p53 and bax/bcl-2 ratio. Therefore, ZnO-NP at a low dosage can provide a protection against the ROS-induced damages and cell death. (Page 14, Lines 299-304)

3. Please indicate the molecular size of ZnT1 and ZIP8 in figure 2. The exact migration position of at least one independent molecular weight marker protein should be indicated with each gel or blot. Each blot panel should retain space above and below the band of interest from the original image.

Response: Thanks for the suggestions. Because of the space limitation, it is difficult to have all of the information in a figure. The original images containing the markers of the Western blots and agarose gels shown in Fig. 2, 3, and 4 were now included in the Supporting Information Figure S3, S4, and S7, respectively.

4. Some spelling errors should be avoided. Such as, in discussion 9th line, “ snRNA” change “shRNA”.

Response: We are sorry for those typos and have checked the spelling of the manuscript carefully, like “German” to “Germany” (Page 5, Line 99), duplicated abbreviation in the abstract (Zinc oxide-nanoparticle (ZnO-NP), now deleted), changed “lose” to “low” (P12, Line 250) etc.

Reviewer #2: Authors investigated the effects of Zinc oxide nanoparticles, which had little cytotoxicity, in cultured human neuroblastoma SH-SY5Y cells and characterized the importance of Zn2+ transporters in 6-hydroxy dopamine (6-OHDA)-induced cell death. The manuscript is well-written, with a significant summary and discussion.

Response: We thank the reviewer’s comments about the effect of ZnO-NP in protecting the cells from 6-OHDA-induced death.

Submitted filename: Response_20200813.docx

Click here for additional data file.

28 Aug 2020

Zinc oxide nanoparticles modulate the gene expression of ZnT1 and ZIP8 to manipulate zinc homeostasis and stress-induced cytotoxicity in human neuroblastoma SH-SY5Y cells

PONE-D-20-11050R1

Dear Dr. Liu,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

2 Sep 2020

PONE-D-20-11050R1

Zinc oxide nanoparticles modulate the gene expression of ZnT1 and ZIP8 to manipulate zinc homeostasis and stress-induced cytotoxicity in human neuroblastoma SH-SY5Y cells

Dear Dr. Liu:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Hsi-Lung Hsieh

Academic Editor

PLOS ONE